---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-029624"
form_type: "8-K"
ticker: null
cik: "0000827871"
company_name: "EAGLE PHARMACEUTICALS, INC."
filed_at: "2024-03-01T23:59:59+00:00"
generated_at: "2026-06-05T05:55:47.205979+00:00"
event_type: "debt"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Eagle Pharma extends credit-agreement financial-statement deadline to May 13; restrictions stay

## Summary
- Second Amendment extends delivery of FY2023 audited and restated Q2/Q3 2023 financials to May 13, 2024.
- Temporary restrictions (reduced availability to $50M, no negative covenant flexibility) continue until both annual and quarterly financials delivered.
- Failure to meet deadline would result in an event of default, allowing lenders to accelerate ~$100M debt and foreclose on assets.
- Company had previously waived minimum-liquidity covenant; remains in ongoing default waiver period under credit agreement.

## SEC filing metadata
- accession: 0001104659-24-029624
- form_type: 8-K
- cik: 0000827871
- company_name: EAGLE PHARMACEUTICALS, INC.
- filed_at: 2024-03-01T23:59:59+00:00
- event_type: debt
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/827871/000110465924029624/0001104659-24-029624-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/827871/000110465924029624/tm247692d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-029624
- JSON: https://secwatch.observer/filing/0001104659-24-029624.json
- Plain text: https://secwatch.observer/filing/0001104659-24-029624.txt

## Key facts
- Material Agreements
  EAGLE PHARMACEUTICALS, INC. amended Second Amendment to Third Amended and Restated Credit Agreement with JPMorgan Chase Bank, N.A., as administrative agent, and the lenders party thereto (effective 2024-02-29).
  - Action: amendment
  - Agreement: credit facility
  - Counterparty: JPMorgan Chase Bank, N.A., as administrative agent, and the lenders party thereto
  - Effective: 2024-02-29
  source text: On February 29, 2024 (the “Amendment Date”), Eagle Pharmaceuticals, Inc. (the “Company”), entered into a Second Amendment to Third Amended and Restated Credit Agreement (the “Second Amendment Agreement”) with JPMorgan Chase Bank, N.A., as administrative agent (the “Agent”), and the lenders party thereto (the “Lenders”), which amends the terms of (i) the Company’s Third Amended and Restated Credit Agreement, dated as of November 1, 2022
  evidence_url: https://www.sec.gov/Archives/edgar/data/827871/000110465924029624/0001104659-24-029624-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.